BeyondSpring Competitors
| BYSI Stock | USD 1.54 0.02 1.28% |
BeyondSpring vs Unicycive Therapeutics Correlation
Very good diversification
The correlation between BeyondSpring and UNCY is -0.37 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding BeyondSpring and UNCY in the same portfolio, assuming nothing else is changed.
Moving against BeyondSpring Stock
| 0.72 | MRKR | Marker Therapeutics | PairCorr |
| 0.72 | CING | Cingulate | PairCorr |
| 0.69 | AEON | AEON Biopharma | PairCorr |
| 0.67 | SNSE | Sensei Biotherapeutics | PairCorr |
| 0.63 | BOLT | Bolt Biotherapeutics | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of BeyondSpring's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
BeyondSpring Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between BeyondSpring and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of BeyondSpring and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of BeyondSpring does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between BeyondSpring Stock performing well and BeyondSpring Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze BeyondSpring's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ALXO | 5.48 | 0.08 | 0.00 | (0.08) | 6.00 | 13.04 | 27.69 | |||
| HYFT | 4.79 | 0.20 | 0.04 | 0.14 | 5.58 | 11.88 | 28.44 | |||
| ATYR | 3.58 | (0.08) | 0.00 | (0.27) | 0.00 | 7.79 | 22.83 | |||
| DTIL | 3.38 | (0.74) | 0.00 | (0.87) | 0.00 | 5.99 | 28.04 | |||
| GUTS | 3.65 | 0.57 | 0.12 | (0.99) | 3.62 | 11.89 | 26.39 | |||
| QNCX | 5.06 | 1.12 | 0.21 | (6.08) | 4.25 | 11.88 | 42.36 | |||
| CAMP | 5.49 | 0.48 | 0.06 | 0.70 | 7.14 | 12.31 | 47.02 | |||
| BMEA | 4.20 | (0.28) | 0.00 | (0.11) | 0.00 | 9.38 | 28.51 | |||
| RPTX | 2.16 | 0.62 | 0.24 | (0.61) | 1.47 | 3.95 | 35.71 | |||
| UNCY | 3.55 | 0.47 | 0.09 | 2.27 | 4.22 | 7.31 | 17.45 |
Cross Equities Net Income Analysis
Compare BeyondSpring and related stocks such as Alx Oncology Holdings, ImmunoPrecise Antibodies, and aTyr Pharma Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALXO | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (19.2 M) | (45.7 M) | (83.5 M) | (123.5 M) | (160.8 M) | (134.8 M) | (121.4 M) | (127.4 M) |
| HYFT | (720.4 K) | (283.1 K) | (95.6 K) | 68 K | (62.5 K) | (34.5 K) | (5.6 M) | (5.2 M) | (7.8 M) | (5.2 M) | (7.3 M) | (17.1 M) | (27.2 M) | (26.4 M) | (30 M) | (27 M) | (25.6 M) |
| ATYR | (17.6 M) | (17.6 M) | (17.6 M) | (20 M) | (24.4 M) | (48 M) | (57.9 M) | (48.2 M) | (34.5 M) | (23.6 M) | (16.2 M) | (33.8 M) | (45.3 M) | (50.4 M) | (64 M) | (57.6 M) | (60.5 M) |
| DTIL | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (21.1 M) | (46 M) | (92.9 M) | (109 M) | (30.6 M) | (111.6 M) | (61.3 M) | 7.2 M | 6.5 M | 6.8 M |
| GUTS | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.5 M) | (38.7 M) | (46.5 M) | (77.1 M) | (68.7 M) | (68.7 M) | (61.8 M) | (64.9 M) |
| QNCX | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (12.5 M) | (37 M) | (76.8 M) | (89.9 M) | (51.7 M) | (31.4 M) | (56.8 M) | (51.1 M) | (53.7 M) |
| CAMP | (5.7 M) | 5.2 M | 44.6 M | 11.8 M | 16.5 M | 16.9 M | (7.2 M) | 16.6 M | 18.4 M | (78.8 M) | (21.2 M) | (31.1 M) | (44.2 M) | (49.3 M) | (51.8 M) | (46.6 M) | (44.3 M) |
| BMEA | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (5.3 M) | (41.2 M) | (80 M) | (117.3 M) | (138.4 M) | (124.6 M) | (118.4 M) |
| RPTX | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (14.3 M) | (27.2 M) | (53.4 M) | (106.9 M) | (29 M) | (93.8 M) | (84.7 M) | (76.2 M) | (80 M) |
| UNCY | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (2.3 M) | (2.5 M) | (10.6 M) | (18.1 M) | (30.5 M) | (36.7 M) | (33.1 M) | (31.4 M) |
BeyondSpring and related stocks such as Alx Oncology Holdings, ImmunoPrecise Antibodies, and aTyr Pharma Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in BeyondSpring financial statement analysis. It represents the amount of money remaining after all of BeyondSpring operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.BeyondSpring Competitive Analysis
The better you understand BeyondSpring competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, BeyondSpring's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across BeyondSpring's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
BeyondSpring Competition Performance Charts
Five steps to successful analysis of BeyondSpring Competition
BeyondSpring's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by BeyondSpring in relation to its competition. BeyondSpring's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of BeyondSpring in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact BeyondSpring's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to BeyondSpring, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your BeyondSpring position
In addition to having BeyondSpring in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Sport Products Thematic Idea Now
Sport Products
Companies manufacturing sporting goods and accessories. The Sport Products theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sport Products Theme or any other thematic opportunities.
| View All Next | Launch |
Check out BeyondSpring Correlation with its peers. For more detail on how to invest in BeyondSpring Stock please use our How to Invest in BeyondSpring guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is there potential for Biotechnology market expansion? Will BeyondSpring introduce new products? Factors like these will boost the valuation of BeyondSpring. Projected growth potential of BeyondSpring fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about BeyondSpring listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.20) | Revenue Per Share | Quarterly Revenue Growth 0.143 | Return On Assets | Return On Equity |
Investors evaluate BeyondSpring using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating BeyondSpring's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause BeyondSpring's market price to deviate significantly from intrinsic value.
It's important to distinguish between BeyondSpring's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding BeyondSpring should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, BeyondSpring's market price signifies the transaction level at which participants voluntarily complete trades.